Rational vaccine development and evaluation requires identifying and measuring the magnitude 17 of epitope-specific CD8 T cell responses. However, conventional CD8 T cell epitope discovery 18 methods are labor-intensive and do not scale well. Here, we accelerate this process by using an 19 ultradense peptide array as a high-throughput tool for screening peptides to identify putative novel 20 epitopes. In a single experiment, we directly assess the binding of four common Indian rhesus 21 macaque MHC class I molecules -Mamu-A1*001, -A1*002, -B*008, and -B*017 -to 22 approximately 61,000 8-mer, 9-mer, and 10-mer peptides derived from the full proteomes of 82 23 simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) isolates.
5 defined for other macaque viruses or bacterial pathogens. While considerably more effort has 87 been dedicated to defining T cell epitopes in humans, these efforts are similarly concentrated on 88 a small number of pathogens (e.g., HIV, influenza) . Methods that facilitate the high-throughput 89 identification of T cell epitopes, particularly for pathogens with large proteomes where T cells play 90 an essential role in protective immunity (e.g., Mycobacterium tuberculosis), are urgently needed.
92
Ultradense peptide arrays have previously been used as a high-throughput tool for assessing 93 antibody responses to pathogens; here, we repurpose them to identify peptides that bind specific 94 MHC class I molecules. Briefly, up to six million linear peptides are synthesized on a single array 95 chip, molecules of interest -antibodies in serum, or other molecules such as MHC proteins -are 96 allowed to bind to the peptides, and binding affinity is reported in fluorescence intensity units 97 based on the detection of fluorophore-conjugated secondary antibodies bound to the molecules.
98
Our group and others have designed arrays to simultaneously assess IgG and IgM binding to 99 linear pathogen-derived peptides (19, 20) . Here, we generated a peptide array with 61,066 unique 100 8-mer, 9-mer, and 10-mer peptides derived from 82 SIV and SHIV isolates, and measured binding 101 to four rhesus macaque MHC class I molecules, Mamu-A1*001, -A1*002, -B*008, and -B*017, all 102 of which have peptide binding repertoires that have been extensively studied by conventional 103 methods. While we focus our attention here on a particular well-studied strain, SIVmac239, as a 7 Materials and Methods 117 SIV/SHIV peptidome array design 118 Peptide sequences were generated from SIV and SHIV amino acid sequences (Supplemental 119 table I). We downloaded 82 SIV and SHIV GenBank files from NCBI and extracted amino acid 120 sequences for all open reading frames into FASTA files. The GenBank SIVmac239 nef protein 121 sequence is truncated and therefore the correct full-length sequence was translated from the full 122 GenBank sequence and added manually. The FASTA files were sent to Roche NimbleGen 123 (Madison, WI; now Nimble Therapeutics) to generate the array. and 124 10-mer peptide sequences were generated with 1-amino acid offsets, and 5 replicates for each 125 peptide were included on the array in a 12-plex array configuration. 
153
To prepare MHC I complexes for peptide array binding, 45 µl di-sodium tetraborate/sodium 154 hydroxide pH 10 buffer (Sigma-Aldrich), 10 µl 2 mg/ml β2M, and 60 µg of MHC class I heavy 155 chain stock were mixed in 400 µl water. This mixture was concentrated with AmiconUltra 0.5 ml,
156
10K centrifugal filter (Millipore) at 12,000 g for 5 min without pre-incubation. Concentrated material 157 was mixed with 400 µl 0.05X pH10 buffer to further dilute urea and 2-ME and concentrated in the 158 same Amicon filter at 12,000 g for 7 min. The concentrated sample was transferred to a 1.5 ml
159
Eppendorf tube, centrifuged at 20,000 g for 5 min to remove precipitated material, and stored at 160 4ºC before binding to the peptide array. peptide replicate were randomly positioned on the array. After synthesis and de-protection, the 166 array was incubated in 0.67 µg/ml Cy5-labeled streptavidin (SA-Cy5) (Amersham), 1% alkali-9 soluble casein (Novagen) at room temperature for 1 hour to stain technical SA-binding features 168 used for array QC and gridding. After a quick rinse in water, the array was dried by spinning in a 169 microcentrifuge equipped with an array holder and a 12-plex incubation chamber was applied to 170 the array surface. Before loading onto the array, MHC I complexes were 1:6 diluted in 20 mM tris-171 HCl, pH7.4, 1% BSA and 6 µl aliquots were loaded into 5 chambers of a 12-plex chamber well.
172
An additional chamber was loaded without the MHC I complexes as a control. The loading ports 173 were sealed with port seals (Grace Bio-Labs, Bend, OR) and the array was incubated at 4ºC 174 overnight. After incubation the chamber was removed, and slides were rinsed in water and stained 175 by dipping with Alexa Fluor 647 MEM-123 1:1,000 (Novus Biologicals, Centennial, CO). After 176 rinsing in water and drying as described above, the array was scanned to collect fluorescence 
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Positive ELISPOT responses were determined as previously described (23).
209
Tetramers and tetramer staining 210 Tetramers conjugated to APC or PE were generously produced by the NIH Tetramer Core Facility 211 using peptides generated by GenScript. Thawed PBMC resuspended to 1 x 10 6 cells/100 µl of 212 R10 medium were stained with tetramers at a concentration of 5 µg/ml in the dark for one hour at (Table I ). Figure 1 shows the complete data for SIVmac239 peptides binding to Mamu-231 A1*001, -A1*002, -B*008, and -B*017, with previously-identified epitopes present in the top 192 232 peptides (out of 9912 SIVmac239 peptides, or 1.9%) for each molecule indicated.
234
Critical residues for Mamu-A1*001 peptide binding identified through substitution analysis 235 Peptide anchor residues define the binding motif for a given MHC molecule and enable prediction 236 of other peptides likely to bind. The binding motif for Mamu-A1*001 was previously defined by 237 sequence analysis of peptides bound to the molecule in vitro and by performing competitive 238 binding assays using peptides with amino acid substitutions (24, 25) . These studies identified 239 positions two and three (P2 and P3), and the C-terminus, as important for binding. We performed 240 a full substitution analysis at each amino acid for two known immunodominant CD8 T cell epitopes 241 that bind to Mamu-A1*001, Gag CM9 (Gag 181-189) and Tat SL8 (Tat 28-35). We tested the 242 influence of all 20 amino acids, plus an amino acid deletion, at each position on the binding of the 243 peptides to Mamu-A1*001 molecules. As would be expected based on prior studies, substitutions 12 at P2 (threonine) and P3 (proline) for both peptides were generally poorly tolerated and resulted 245 in dramatically decreased signal intensity, indicating reduced binding affinity (Figure 2) . At P2, a 246 substitution with serine was tolerated; P3 did not tolerate any substitutions. These results 247 corroborated those found by competitive binding assays using Gag CM9 peptides with single 248 amino acid substitutions (24). A previous study found that L, I, V, M, F, W, Y, and T are tolerated 249 at the C-terminus; however, this study did not test every possible amino acid at that position, and 250 our results suggest that R, K, and H may also be tolerated (24).
252
Measuring IFN-γ ELISPOT responses to SIVmac239 peptides that bind to Mamu-A1*001
253
We assessed whether the MHC peptide array can be used to efficiently screen for putative novel 254 CD8 T cell epitopes by performing IFN-γ ELISPOTs for top-binding peptides. We tested six 
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To quantify and confirm these responses, we produced Mamu-A1*001 tetramers folded with Gag 269 CM9, Tat SL8, and the three peptides identified by ELISPOT. We tested these for CD8 T cell 270 13 binding using PBMCs from two Mamu-A1*001-positive animals whose cells we used in our
271
ELISPOT experiments (one animal that did and one that did not show responses to the three 272 ELISPOT-positive peptides) and one animal that did not have Mamu-A1*001. For Gag CM9, Tat 273 SL8, STPESANLG, and STPESANLGE (but not TPESANLGE), we identified populations of 
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We additionally compared Mamu-A1*001 binding at the region corresponding to the SIVmac239
291
Tat SL8 epitope across all viruses on the array. CD8 T cell responses to the SL8 epitope in 292 animals carrying the Mamu-A1*001 allele have been associated with suppression of viral 293 replication, and mutations in this region are commonly implicated in viral escape (26, 27) .
294
Identifying whether Mamu-A1*001 is likely to be able to bind to this region despite amino acid 295 sequence differences will be important in determining whether this epitope region is likely to be 296 14 immunodominant in viral strains other than SIVmac239. SIVmac251 strains, also commonly used 297 in research, are split between having the SL8 sequence and TTPESANL (TL8). TL8 has 298 previously been found to be immunodominant; however, this was first established in experiments 299 studying macaques infected with SIVmac239 -suggesting that there is some latitude in Mamu-300 A1*001's ability to bind to that region (13). The peptide array results affirm TL8 as a strong binder 301 to Mamu-A1*001, with a higher binding score (8.72) than SL8 (8.33). We found that all SIVsm 302 (isolated from sooty mangabeys) strains had the sequence PTPESANL (PL8), an escape variant 303 seen in SIVmac239 infection that exhibits reduced binding to Mamu-A1*001 (27) . Similarly, on 304 our array we found that PL8 had a lower binding score than SL8 and TL8 (6.28), but one that was 
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we expect these values to correlate with those obtained from competitive binding assays, recent 314 studies have found that IC50 values do not accurately estimate kd values, making it challenging to 315 make a direct comparison between IC50 and fluorescence intensity units (28). However, using the 316 IC50 data available in the literature for peptides tested for binding to Mamu-A1*001, -A1*002, -317 B*008, and -B*017, we do find that peptide array binding scores for peptides that were previously 318 found to bind an MHC molecule (IC50 ≤ 500 nM) were significantly higher (Median = 0.51; 95% 319 CI = 0.34, 0.70; p < 0.001, using a Wilcoxon rank-sum test) than for those that did not bind MHC 320 (IC50 > 500 nM) (Figure 4) 
331
Compared to conventional methods, ultradense peptide arrays provide massive amounts of 332 information regarding binding of class I MHC molecules to thousands of individual peptides in a 333 single experiment. In this study, of the 86 peptides that bound Mamu-A1*001 with the highest 334 fluorescence intensity scores on the array, we identified 10 peptides that were positive in at least 335 one animal and three that were positive in three animals using IFN-γ ELISPOTs and PBMCs from 336 four SIVmac239-infected Mamu-A1*001-positive rhesus macaques. These peptides were not 337 reported as epitopes previously, thus demonstrating the power of the peptide array method as an 338 alternative approach to screen for putative novel immunogenic epitopes. We additionally 339 demonstrate that many of the same epitopes previously found to bind each molecule and induce 340 CD8 T cell responses were identified as high-binding peptides in our array; 27-64% of the 341 previously-identified epitopes for each MHC molecule were found in the top 192 high-binding 342 peptides on our array.
344
Despite these initial promising results, many known epitopes were not detected by our method.
345
This may be due in part to the choice of 192 peptides as a convenient cutoff for "high binding."
346
Because the peptide array binding scores do not directly correspond to IC50 values from 347 competitive binding assays, we refrain from choosing a hard binding score cutoff to distinguish 348 binding from non-binding peptides. While there was a significant difference (p < 0.001) in 349 fluorescence intensity values between peptides that were previously found to bind or not bind to 350 MHC molecules based on competitive binding assays, there were some instances where 351 17 fluorescence intensity values did not reflect the results of the competitive binding assays. For 352 example,the Tat SL8 epitope's high fluorescence intensity (7.15 sd above the median for Mamu-353 A1*001) and low IC50 value both indicate strong peptide binding. However, the Gag CM9 epitope 354 showed a substantially lower fluorescence intensity (2.36 sd above the median for Mamu-355 A1*001), but also had a low IC50 value. These discrepancies may be attributable to differences in 356 how certain peptides or MHC molecules perform on the array; certainly, it would be reasonable 357 to expect that some differences may arise because peptides are anchored on the array rather 358 than free-floating. Unfortunately, neither competitive binding assays nor peptide arrays truly mimic 359 in vivo MHC-peptide binding, so without further optimization of the method, it would be premature 360 to label one method as "more true" than the other.
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We tested a portion of the high-binding peptides identified here by IFN-γ ELISPOT as a proof of 363 concept. We identified three SIVmac239 peptides that strongly bound Mamu-A1*001 that had 364 positive responses in at least two animals and were not previously identified epitopes; two of the 365 tetramers generated to test these responses were functional. All three peptides overlapped the 366 Tat SL8 epitope, and the two functional tetramers had weaker responses than the SL8 tetramer, 367 which may suggest that these are not separate epitopes but simply extensions of the SL8 minimal 368 optimal epitope. Still, this indicates that a researcher using the array to look for MHC binding to 369 an unknown pathogen's proteome could reasonably expect to find CD8 T cell epitopes in a subset 370 of high-binding peptides identified by the array; moreover, this demonstrates that, at least in some 371 cases, peptide binding to clusters of related sequences (ie., 8-mer, 9-mer, and 10-mer peptides 
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CD8 T cell responses are not the sole arbiter of protective immunity in HIV vaccination; a better 378 understanding of CD4 responses is necessary for developing a more comprehensive picture of 379 the determinants of a successful vaccine. Assessing CD4 T cell responses in PBMCs and 380 developing class II tetramers is currently more difficult than for CD8 T cells and class I MHC.
381
While this will present challenges in validating a class II array, it underscores the need for a 382 method for rapidly screening for potential CD4 T cell responses, and optimizing a class II array 383 will be an important future direction.
385
Ultradense peptide arrays offer a method for rapidly mapping class I MHC binding to thousands Table I A 
